Literature DB >> 10224296

Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia.

R Uddman1, J Tajti, S Möller, F Sundler, L Edvinsson.   

Abstract

A majority of the parasympathetic nerve fibers to cranial structures derive from the sphenopalatine and otic ganglia. In particular, blood vessels are invested with a rich supply of dilator fibers of parasympathetic origin. In the present study, we have examined the occurrence of noncholinergic neuromessengers and neuropeptide receptors in the human sphenopalatine and otic ganglia. Vasoactive intestinal peptide (VIP)-immunoreactive (ir) nerve cell bodies occurred in high numbers in the sphenopalatine and otic ganglia. Likewise, high numbers of NOS- and PACAP-containing nerve cell bodies were seen in both ganglia. Autofluorescent lipofuscin, characteristic of adult human nervous tissue, was present within many nerve cell bodies in both ganglia. Receptor mRNA was studied with reverse transcriptase-polymerase chain reaction (RT-PCR). Total RNA from the sphenopalatine and otic ganglia was successfully extracted. By using appropriate sense and antisense primers, oligonucleotides were designed from the human sequences derived from GenBank, corresponding to human NPY Y1, CGRP1 and VIP1 receptors. In the sphenopalatine ganglion, we revealed the presence of mRNA for the human NPY Y1 and VIP1 receptors but not the CGRP1 receptor. The otic ganglion was found to react positively only for primers to mRNA for VIP1 but not for CGRP1 or NPY Y1 receptors. Copyright 1999 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10224296     DOI: 10.1016/s0006-8993(99)01260-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  19 in total

Review 1.  The PACAP receptor: a novel target for migraine treatment.

Authors:  Henrik W Schytz; Jes Olesen; Messoud Ashina
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 2.  Emerging Treatment Targets for Migraine and Other Headaches.

Authors:  Zachariah Bertels; Amynah Amir Ali Pradhan
Journal:  Headache       Date:  2019-07       Impact factor: 5.887

Review 3.  Parasympathetic innervation of vertebrobasilar arteries: is this a potential clinical target?

Authors:  Eva V L Roloff; Ana M Tomiak-Baquero; Sergey Kasparov; Julian F R Paton
Journal:  J Physiol       Date:  2016-10-05       Impact factor: 5.182

Review 4.  Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine.

Authors:  Tahlia Sundrum; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2017-10-25       Impact factor: 8.739

Review 5.  Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine.

Authors:  Anne Luise Haulund Vollesen; Faisal Mohammad Amin; Messoud Ashina
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

6.  The origin of extrinsic nitrergic axons supplying the human eye.

Authors:  Johannes Gottanka; Wolfram Kirch; Ernst R Tamm
Journal:  J Anat       Date:  2005-03       Impact factor: 2.610

7.  Voltage-dependent calcium channels are involved in neurogenic dural vasodilatation via a presynaptic transmitter release mechanism.

Authors:  S Akerman; D J Williamson; P J Goadsby
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

8.  Electrophysiological and immunofluorescence characterization of Ca(2+) channels of acutely isolated rat sphenopalatine ganglion neurons.

Authors:  Wojciech Margas; Victor Ruiz-Velasco
Journal:  Neurosci Lett       Date:  2007-05-04       Impact factor: 3.046

Review 9.  Neurovascular contributions to migraine: Moving beyond vasodilation.

Authors:  Blaine Jacobs; Gregory Dussor
Journal:  Neuroscience       Date:  2016-06-14       Impact factor: 3.590

Review 10.  Effect of PACAP in central and peripheral nerve injuries.

Authors:  Andrea Tamas; Dora Reglodi; Orsolya Farkas; Erzsebet Kovesdi; Jozsef Pal; John T Povlishock; Attila Schwarcz; Endre Czeiter; Zalan Szanto; Tamas Doczi; Andras Buki; Peter Bukovics
Journal:  Int J Mol Sci       Date:  2012-07-06       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.